瑞桑基祖马布在克罗恩病中 ustekinumab 失败后是有效的:来自第三级中心的现实研究
Michael Colwill1,2, Jessica Padley1, Umang Qazi1
1Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London SW17 0QT, United Kingdom.
World journal of gastrointestinal pharmacology and therapeutics
|December 11, 2025
概括
切换到risankizumab改善了以前用ustekinumab治疗的患者克罗恩病的控制. 这种治疗提供了显著的临床益处,特别是对于那些二次响应丧失的人.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 克罗恩病 (CD) 是一种慢性炎症状况,需要先进的治疗方法.
- 关于瑞桑基祖马布和乌斯特基努马布等治疗方法的优越性和顺序的数据有限.
- 在 ustekinumab 在现实世界 CD 管理中失败后切换到 risankizumab 的疗效尚不清楚.
研究的目的:
- 评估从乌斯特基努马布切换到里桑基祖马布在克罗恩氏病患者活跃疾病的有效性.
- 评估切换后的临床,生化和内镜结果.
主要方法:
- 对已成年CD患者的回顾性审查,这些患者从ustekinumab转换为risankizumab.
- 使用哈维-布拉德肖指数 (HBI),C反应蛋白 (CRP),白蛋白和便calprotectin评估疾病活动.
- 在基线和转换后的3,6和9个月收集的数据.
主要成果:
- 在9个月后,HBI显著下降,临床缓解率增加 (37.1%至94.4%).
- 专蛋白水平显著改善;CRP和便calprotectin的数值改善.
- 在对ustekinumab的二次响应丧失 (SLOR) 患者中观察到优异的反应.
结论:
- 切换到risankizumab在之前接受了ustekinumab的活跃CD患者中显示出显著的临床和生化改善.
- 实现了高缓解率,特别是在SLOR.患者中.
- 瑞桑基祖马布是 ustekinumab 治疗失败后耐火性 CD 的可行和有效选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Inflammatory Bowel Disease II: Crohn's Disease
915
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
915
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380


